Insulet Corporation

NASDAQ:PODD

Medical - Devices

Healthcare
$139.98 -2.82%

-$4.17 today

Market cap
$9.71B
Beta
1.13
P/E (TTM)
33.2
EPS (TTM)
$4.33
52W Low $140.63High $354.88

Volume 2.09M

Average 1.32M

PODD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Insulet CorporationNASDAQ: PODD

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $88.1M rose 20.0% year over year, behind the +39.2% change in trailing-twelve-month research & development. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +18.7% a year.

Context

  • Research & development amounted to 11.1% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +20.0% toward the trailing-twelve-month pace of +39.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$88.1M-1.8% QoQ
Last fiscal yearDec 2025
$301.1M+37.1% YoY
LTMJun 2026
$345.9M+39.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.0%——
1 year+37.1%——
3-year CAGR+18.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
301.1M USD
Year-over-year change
+37.1%
4-year CAGR
+17.1%

Research & Development vs competitors

How PODD compares with its peers on the latest reported figures

  • PODD's LTM Jun 2026 research & development of $345.9M is the 2nd highest of the 5 companies compared; the peer median is $112.83M.
  • Its year-over-year change of +39.2% is the highest of 5, against a peer median of -3.6%.
  • Research & development amounts to 11.3% of revenue for PODD, versus a peer median of 26.2%.
PODD Competitors Peer median
Research & Development for PODD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$604M +6.3%+7.4%12.2%
PODDInsulet CorporationLTM Jun 2026$345.9M +39.2%+18.7%11.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$188.1M -32.4%+0.9%18.3%
BBNXBeta Bionics, Inc.LTM Mar 2026$37.56M +32.7%+3.4%34.1%
SENSSenseonics Holdings, Inc.LTM Mar 2026$32.9M -13.4%-7.3%80.8%
Peer median (excluding PODD) $112.83M-3.6%+2.2%26.2%

Competitors are the stored peer set for PODD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.31B1.7B2.07B2.71B
Cost of Revenue346.7M499.7M537.2M625.9M768.2M
Gross Profit752.1M805.6M1.16B1.45B1.94B
Gross Margin68.4%61.7%68.3%69.8%71.6%
Research & Development160.1M180.2M205M219.6M301.1M
Selling, General & Admin466M587.8M734.9M917.2M1.17B
Operating Expenses626.1M768M939.9M1.14B1.47B
Depreciation & Amortization57.4M63.2M72.8M80.8M90.4M
EBITDA139.6M109M323.6M423.7M509.6M
EBITDA Margin12.7%8.4%19.1%20.5%18.8%
Operating Income126M37.6M220M308.9M473.8M
Operating Margin11.5%2.9%13.0%14.9%17.5%
Interest Income500K9.3M28.6M39.5M34.7M
Interest Expense61.7M36M36.2M42.7M79.7M
Other Income / Expenses(105.5M)(27.8M)(5.4M)(8.7M)(134.3M)
Income Before Tax20.5M9.8M214.6M300.2M339.5M
Pre-Tax Margin1.9%0.8%12.6%14.5%12.5%
Income Tax Expense3.7M5.2M8.3M(118.1M)92.4M
Net Income16.8M4.6M206.3M418.3M247.1M
Net Margin1.5%0.4%12.2%20.2%9.1%
EPS (Basic)0.250.072.965.973.51
EPS (Diluted)0.250.072.945.783.48
Weighted Avg Shares67.7M69.38M69.75M70.08M70.35M
Weighted Avg Shares (Diluted)68.58M69.91M73.63M73.89M71.89M

Insulet Corporation

NASDAQ:PODD

Intrinsic Alpha fair value

Locked

Current Price

$139.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.